Vontobel Holding Ltd. Boosts Stake in Johnson & Johnson $JNJ

Vontobel Holding Ltd. increased its position in Johnson & Johnson (NYSE:JNJ) by 11.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 602,178 shares of the company’s stock after purchasing an additional 63,442 shares during the quarter. Vontobel Holding Ltd.’s holdings in Johnson & Johnson were worth $111,656,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. lifted its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth about $35,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth about $48,000. Finally, Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Johnson & Johnson by 66.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after purchasing an additional 150 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Barclays upped their price target on Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Wells Fargo & Company increased their target price on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Raymond James Financial upped their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Finally, Citigroup raised their price objective on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $210.25.

Johnson & Johnson Price Performance

NYSE JNJ opened at $208.01 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18. The stock has a 50-day moving average of $199.39 and a 200 day moving average of $180.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $501.14 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 2.25 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.